Michel  Fontés

Dr. Michel Fontés

Obesity and Risk of Thrombosis Laboratory, Aix Marseille Universite, Marseille, France

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2014 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PDF file
FRFryad Rahman
Fryad Rahman
FFFadi Al Frouh
Fadi Al Frouh
BBBenoit Bordignon
Benoit Bordignon
MFMarc Fraterno
Marc Fraterno
Jean-Francois LandrierJean-Francois Landrier
Jean-Francois Landrier
Michel  FontésMichel Fontés
Michel Fontés
Ascorbic acid (AA) is the active component of vitamin C and antioxidant activity was long considered to be the primary molecular mechanism underlying the physiological actions of AA. We recently demonstrated that AA is a competitive inhibitor of adenylate cyclase, acting as a global regulator of intracellular cyclic adenosine monophosphate (cAMP) levels. Our study, therefore, aimed to determine new targets of AA that would account for its potential effect on signal transduction, particularly during cell differentiation. We demonstrated that AA is an inhibitor of pre-adipocyte cell line differentiation, with a dose-dependent effect. Additionally, we describe the impact of AA on the expression of genes involved in adipogenesis and/or the adipocyte phenotype. Moreover, our data suggest that treatment with AA partially reverses lipid accumulation in mature adipocytes. These properties likely reflect the function of AA as a global regulator of the cAMP pool, since an analog of AA without any antioxidant properties elicited the same effect. Additionally, we demonstrated that AA inhibits adipogenesis in OP9 mesenchymal cell line and drives the differentiation of this line toward osteogenesis. Finally, our data suggest that the intracellular transporter SVCT2 is involved in these processes and may act as a receptor for AA.

15 February 2017 in Molecular Nutrition & Food Research
Verified
Journal Article
Closed access
PDF file
FRFryad Rahman
Fryad Rahman
BBBenoit Bordignon
Benoit Bordignon
RCRaphael Culerrier
Raphael Culerrier
FPFranck Peiretti
Franck Peiretti
SSSalvatore Spicuglia
Salvatore Spicuglia
Michel  FontésMichel Fontés
Michel Fontés

Verified
Journal Article
Open access
PDF file
PMPierre Miniou
Pierre Miniou
Michel  FontésMichel Fontés
Michel Fontés
Charcot–Marie–Tooth disease (CMT) is the most frequent hereditary peripheral neuropathies. It is subdivided in two main groups, demyelinating (CMT1) and axonal (CMT2). CMT1 forms are the most frequent. The goal of this review is to present published data on 1—cellular and animal models having opened new potential therapeutic approaches. 2—exploration of these tracks, including clinical trials. The first conclusion is the great increase of publications on CMT1 subtypes since 2000. We discussed two points that should be considered in the therapeutic development toward a regulatory-approved therapy to be proposed to patients. The first point concerns long term safety if treatments will be a long-term process. The second point relates to the evaluation of treatment efficiency. Degradation of CMT clinical phenotype is not linear and progressive.

13 June 2014 in Frontiers in Neuroscience
Verified
Journal Article
Open access
PDF file
SMSaleh Mones
Saleh Mones
BBBenoit Bordignon
Benoit Bordignon
FPFranck Peiretti
Franck Peiretti
Jean-Francois LandrierJean-Francois Landrier
Jean-Francois Landrier
BGBurkhardt Gess
Burkhardt Gess
Michel  FontésMichel Fontés
Michel Fontés
Mutation in the Gjb1 gene, coding for a connexin (Cx32), is associated with an inherited peripheral neuropathic disorder (X-linked Charcot-Marie-Tooth, CMTX). Our previous work reported that transgenic animals expressing a human Gjb1 transgene present polyploidy and abnormal over-duplication of the centrosome, suggesting a role for Gjb1 in mitotic stability. In this article, we propose mechanisms by which mutations in Gjb1 induce mitotic instability and discuss its potential relation with the CMTX phenotype. We showed that transgenic cells exhibit CamKII over-stimulation, a phenomenon that has been linked to mitotic instability (polyploidy, nuclear volume and centrosome over-duplication), that is reversed by CamKII inhibitors. We also demonstrate that connexon activity is partially restored in transgenic cells with CamKII inhibitors. Our model supports the role for Pim1, a kinase that has been associated with genomic instability in cancers, in genomic instability in Cx32 mutations. Regarding in vivo phenotype, we showed that degradation on the rotarod test in our transgenic mice is significantly lowered by treatment with a CamKII inhibitor (KN93). This effect was seen in two lines with different point mutations in GJB1, and stopping the treatment by KN93 led to degradation of the phenotype.

Verified
Journal Article
Open access
PDF file
Michel  FontésMichel Fontés
Michel Fontés
Peripheral neuropathies are subdivided into acquired and hereditary transmitted disorders.

7 May 2015 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
MSMones Saleh
Mones Saleh
BGBurkhard Gess
Burkhard Gess
BBBordignon Benoit
Bordignon Benoit
AAAlexandre Altié
Alexandre Altié
YPYoung Peter
Young Peter
Michel  FontésMichel Fontés
Michel Fontés
We previously described that fibroblasts from animal models of CMTX1 present genomic instability and poor connexon activity. In vivo, these transgenic mice present motor deficits. This phenotype could be significantly reverted by treatment with (CamKII) inhibitors. The objective of this study is to translate our findings to patients. We cultured fibroblasts from skin biopsies of CMTX1 patients and analyzed cells for genomic instabilty, connexon activity, and potential correction by CamKII inhibitors. The phenotypic analysis of these cells confirmed strong similarities between the GJB1 transgenic mouse cell lines and CMTX1 patient fibroblast cell lines. Both present mitotic anomalies, centrosome overduplication, and connexon activity deficit. This phenotype is corrected by CamKII inhibitors. Our data demonstrate that fibroblasts from CMTX1 patients present a phenotype similar to transgenic lines that can be corrected by CamKII inhibitors. This presents a track to develop therapeutic strategies for CMTX1 treatment.